NIKKEI 225
27,448.01-699.50(-2.49%)HANG SENG
27,718.67-512.37(-1.81%)CRUDE OIL
63.68-2.40(-3.63%)
Aerie Pharmaceuticals, Inc. (AERI)
| Previous close | 17.59 |
| Open | 17.69 |
| Bid | 17.89 x 900 |
| Ask | 17.90 x 800 |
| Day's range | 17.53 - 18.29 |
| 52-week range | 9.01 - 21.30 |
| Volume | 222,738 |
| Avg. volume | 569,719 |
| Market cap | 838.335M |
| Beta (5Y monthly) | 0.71 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.83 |
| Earnings date | 04 Aug 2021 - 09 Aug 2021 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 27.25 |
- Zacks
Aerie's (AERI) Q1 Loss Wider Than Expected, Revenues Miss
Aerie (AERI) incurs a wider loss in the first quarter of 2021 and sales miss expectations.
- Business Wire
Aerie Pharmaceuticals to Participate in the Bank of America Securities 2021 Healthcare Conference
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced that Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer, will present in a fireside discussion at the Bank of America Securities 2021 Healthcare Conference on Wednesday, May 12, 2021 at 9:30 a.m. Eastern Time. Dr. Anido will provide an Aerie overview and business update.
- Zacks
Aerie Pharmaceuticals (AERI) Reports Q1 Loss, Misses Revenue Estimates
Aerie (AERI) delivered earnings and revenue surprises of -4.35% and -1.64%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
